JP2019529420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529420A5 JP2019529420A5 JP2019514777A JP2019514777A JP2019529420A5 JP 2019529420 A5 JP2019529420 A5 JP 2019529420A5 JP 2019514777 A JP2019514777 A JP 2019514777A JP 2019514777 A JP2019514777 A JP 2019514777A JP 2019529420 A5 JP2019529420 A5 JP 2019529420A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- combination according
- administered
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 27
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 24
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 10
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 10
- 229960000684 cytarabine Drugs 0.000 claims description 10
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 10
- 101150098203 grb2 gene Proteins 0.000 claims description 10
- 201000005787 hematologic cancer Diseases 0.000 claims description 9
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 8
- 229960002448 dasatinib Drugs 0.000 claims description 8
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 claims description 7
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 5
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 4
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 229960003603 decitabine Drugs 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 230000014621 translational initiation Effects 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- 239000003840 Bafetinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 229950002365 bafetinib Drugs 0.000 claims description 2
- ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 claims description 2
- 229960003736 bosutinib Drugs 0.000 claims description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001131 ponatinib Drugs 0.000 claims description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 62
- 238000002651 drug therapy Methods 0.000 description 30
- 150000003626 triacylglycerols Chemical class 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395680P | 2016-09-16 | 2016-09-16 | |
| US62/395,680 | 2016-09-16 | ||
| US201762487277P | 2017-04-19 | 2017-04-19 | |
| US62/487,277 | 2017-04-19 | ||
| PCT/US2017/051723 WO2018053232A1 (en) | 2016-09-16 | 2017-09-15 | Combination therapy with liposomal antisense oligonucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529420A JP2019529420A (ja) | 2019-10-17 |
| JP2019529420A5 true JP2019529420A5 (enExample) | 2020-09-24 |
| JP7132911B2 JP7132911B2 (ja) | 2022-09-07 |
Family
ID=61619722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514777A Active JP7132911B2 (ja) | 2016-09-16 | 2017-09-15 | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10927379B2 (enExample) |
| EP (1) | EP3512525B1 (enExample) |
| JP (1) | JP7132911B2 (enExample) |
| KR (1) | KR20190053905A (enExample) |
| CN (1) | CN109963571A (enExample) |
| AU (2) | AU2017325971A1 (enExample) |
| BR (1) | BR112019005166A2 (enExample) |
| CA (1) | CA3034637A1 (enExample) |
| ES (1) | ES2928654T3 (enExample) |
| MX (1) | MX2019003070A (enExample) |
| SG (2) | SG11201901667TA (enExample) |
| WO (1) | WO2018053232A1 (enExample) |
| ZA (1) | ZA201902079B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| US12234457B2 (en) * | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| EP4213948A4 (en) * | 2020-09-16 | 2024-12-25 | Board of Regents, The University of Texas System | Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair |
| CN112891376B (zh) * | 2021-03-09 | 2023-02-03 | 阜阳天祥食品科技有限公司 | 羊油在制备治疗肺癌药品中的应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959463A (en) | 1985-10-15 | 1990-09-25 | Genentech, Inc. | Intermediates |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
| US4816571A (en) | 1987-06-04 | 1989-03-28 | Applied Biosystems, Inc. | Chemical capping by phosphitylation during oligonucleotide synthesis |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5602244A (en) | 1988-05-26 | 1997-02-11 | Competitive Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| US5248671A (en) | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5708154A (en) | 1989-02-24 | 1998-01-13 | City Of Hope | RNA-DNA hybrid molecules of nucleic acid |
| US5141813A (en) | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
| DE69033495T2 (de) | 1989-10-24 | 2000-07-20 | Isis Pharmaceuticals, Inc. | 2'-modifizierte nukleotide |
| US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5872232A (en) | 1990-01-11 | 1999-02-16 | Isis Pharmaceuticals Inc. | 2'-O-modified oligonucleotides |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| CA2088258C (en) | 1990-07-27 | 2004-09-14 | Phillip Dan Cook | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US6111094A (en) | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5766855A (en) | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| JPH07504087A (ja) | 1992-02-12 | 1995-05-11 | クロマジェン インク | 蛍光性ｎ−ヌクレオシド及び蛍光性ｎ−ヌクレオシド構造類似体の応用 |
| US5652099A (en) | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
| US5428148A (en) | 1992-04-24 | 1995-06-27 | Beckman Instruments, Inc. | N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis |
| GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
| US5438131A (en) | 1992-09-16 | 1995-08-01 | Bergstrom; Donald E. | 3-nitropyrrole nucleoside |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| AU683957B2 (en) | 1993-11-05 | 1997-11-27 | Amgen, Inc. | Liposome preparation and material encapsulation method |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5574146A (en) | 1994-08-30 | 1996-11-12 | Beckman Instruments, Inc. | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators |
| US5554744A (en) | 1994-09-23 | 1996-09-10 | Hybridon, Inc. | Method for loading solid supports for nucleic acid synthesis |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
| US5670663A (en) | 1996-02-14 | 1997-09-23 | Regents Of The University Of California | Recovery of taxanes from conifers |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5908845A (en) | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
| US7262173B2 (en) | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| WO2000040592A1 (en) | 1998-12-30 | 2000-07-13 | Oligos Etc. Inc. | Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| US20030180789A1 (en) | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| US20050186264A1 (en) | 2000-10-12 | 2005-08-25 | Kiani Mohammad F. | Targeting drug/gene carriers to irradiated tissue |
| US7060690B2 (en) | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| KR101265180B1 (ko) | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US8969314B2 (en) | 2003-07-31 | 2015-03-03 | Regulus Therapeutics, Inc. | Methods for use in modulating miR-122a |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20080171718A1 (en) | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
| US8349812B2 (en) | 2007-11-06 | 2013-01-08 | Adiutide Pharmaceuticals Gmbh | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| US20110263609A1 (en) * | 2007-11-15 | 2011-10-27 | Alfonso Quintas-Cardama Lee | Methods of Identifying and Treating Individuals Exhibiting NUP214-ABL1 Positive T-Cell Malignancies with Protein Tyrosine Kinase Inhibitors and Combinations Thereof |
| JP5766608B2 (ja) * | 2008-10-02 | 2015-08-19 | ヴェーイーベー ヴェーゼットウェーＶｉｂ Ｖｚｗ | フィラデルフィア染色体陽性白血病を治療するためのＰｌＧＦの阻害 |
| WO2012024396A2 (en) | 2010-08-17 | 2012-02-23 | Rutgers, The State University Of New Jersey | Compositions and methods for delivering nucleic acid molecules and treating cancer |
| EP2670396A1 (en) * | 2011-01-31 | 2013-12-11 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| WO2012122447A1 (en) | 2011-03-09 | 2012-09-13 | The Brigham And Women's Hospital, Inc. | Methods of using microrna-26a to promote angiogenesis |
| MY163004A (en) | 2011-04-01 | 2017-07-31 | Ionis Pharmaceuticals Inc | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| EP2638911A1 (en) * | 2012-03-14 | 2013-09-18 | Sanofi | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
| US10154962B2 (en) | 2013-06-03 | 2018-12-18 | Bar Ilan University | Liposomes for modulating Wiskott-Aldrich syndrome protein |
| MX389323B (es) | 2013-12-03 | 2025-03-20 | Univ Northwestern | Particulas liposomales, metodos para elaborarlas y sus usos. |
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| BR112019018555A2 (pt) | 2017-03-09 | 2020-04-14 | Univ Jefferson | métodos e composições para tratamento de cânceres utilizando antissenso |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| CN110650727A (zh) | 2017-04-19 | 2020-01-03 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| JP2020517645A (ja) | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス， インコーポレイテッド | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
| MX2021011760A (es) | 2019-03-28 | 2021-12-10 | Univ Jefferson | Metodos para el tratamiento de canceres usando antisentido. |
| CN112830354A (zh) | 2019-11-22 | 2021-05-25 | 富泰华工业（深圳）有限公司 | 基于区块链系统的电梯调度系统、装置、方法及存储介质 |
-
2017
- 2017-09-15 US US16/333,221 patent/US10927379B2/en active Active
- 2017-09-15 SG SG11201901667TA patent/SG11201901667TA/en unknown
- 2017-09-15 JP JP2019514777A patent/JP7132911B2/ja active Active
- 2017-09-15 AU AU2017325971A patent/AU2017325971A1/en not_active Abandoned
- 2017-09-15 WO PCT/US2017/051723 patent/WO2018053232A1/en not_active Ceased
- 2017-09-15 BR BR112019005166-0A patent/BR112019005166A2/pt active Search and Examination
- 2017-09-15 SG SG10202008771WA patent/SG10202008771WA/en unknown
- 2017-09-15 KR KR1020197010647A patent/KR20190053905A/ko not_active Ceased
- 2017-09-15 MX MX2019003070A patent/MX2019003070A/es unknown
- 2017-09-15 ES ES17851584T patent/ES2928654T3/es active Active
- 2017-09-15 CN CN201780063395.1A patent/CN109963571A/zh active Pending
- 2017-09-15 EP EP17851584.7A patent/EP3512525B1/en active Active
- 2017-09-15 CA CA3034637A patent/CA3034637A1/en active Pending
-
2019
- 2019-04-03 ZA ZA2019/02079A patent/ZA201902079B/en unknown
-
2021
- 2021-01-15 US US17/150,151 patent/US12012601B2/en active Active
-
2023
- 2023-08-14 AU AU2023214401A patent/AU2023214401B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529420A5 (enExample) | ||
| ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2012521435A5 (enExample) | ||
| JP2005533029A5 (ja) | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン | |
| JP2010180210A5 (enExample) | ||
| US20200384007A1 (en) | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof | |
| JP2012522837A5 (enExample) | ||
| CN104582708A (zh) | 用于治疗小细胞肺癌的苯并二氮*类 | |
| JP2019510785A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| ES2340021T3 (es) | Tratamiento del carcinoma renal metastatico. | |
| JP2010525042A (ja) | 増殖性疾患を治療するためのサパシタビンの使用 | |
| PT1839662E (pt) | Agente antitumoral | |
| ES2369535T3 (es) | Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. | |
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| RU2018131377A (ru) | Способ, включающий фиксированное дробное дозирование цедираниба | |
| JP2002326936A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| CN103442708B (zh) | 治疗性处理 | |
| RU2016116915A (ru) | Комбинация | |
| JP7027448B2 (ja) | 血液癌治療剤 | |
| ES2299841T3 (es) | Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos. | |
| WO2013137433A1 (ja) | ３剤を組み合わせた新規な抗腫瘍剤 | |
| EP3784230A2 (en) | The use of terpenic coumarine derivative molecules in the treatment of cancer disease | |
| Delfino et al. | Combination treatment in CTCL: the current role of bexarotene |